Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.76 |
| ▸ | NPC1 | O15118 | 9/20 | 0.76 |
| ▸ | RAB9A | P51151 | 9/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.76 |
| ▸ | HPGD | P15428 | 7/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.76 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.76 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.76 |
| ▸ | RELA | Q04206 | 2/20 | 0.76 |
| ▸ | ATM | Q13315 | 1/20 | 0.76 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 7/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18003207 | 0.87 | GPR119 (0.62) | MAPTNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL1675479 | 0.86 | NPC1 (0.64) | MAPTNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL31247990 | 0.86 | KDM4E (0.74) | MAPTNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL28605620 | 0.86 | KDM4E (0.74) | MAPTNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL1675543 | 0.85 | MAPT (0.66) | MAPTNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL9608577 | 0.82 | GPR119 (0.52) | MAPTNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL144958 | 0.82 | MAPT (0.71) | MAPTNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL20897861 | 0.82 | MAPT (0.60) | MAPTNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL20898075 | 0.82 | MAPT (0.60) | MAPTNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL5834871 | 0.82 | RAB9A (0.62) | MAPTNPC1RAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269191-A1 | Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269191-A1 | Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1812071-A2 | COMPOUNDS FOR NONSENSE SUPPRESSION, USE OF THESE COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC Therapeutics, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006044503-A2 | COMPOUNDS FOR NONSENSE SUPPRESSION, USE OF THESE COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC THERAPEUTICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269191-A1 | Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | UPF1, NSUN2, RNMT | MAPT 2955/4885NPC1 971/4885RAB9A 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.